Kamada Ltd. (KMDA) Expected to Announce Quarterly Sales of $24.84 Million
Wall Street brokerages expect Kamada Ltd. (NASDAQ:KMDA) to post $24.84 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Kamada’s earnings, with the lowest sales estimate coming in at $24.50 million and the highest estimate coming in at $25.18 million. Kamada reported sales of $19.37 million during the same quarter last year, which indicates a positive year over year growth rate of 28.2%. The firm is expected to report its next earnings results on Thursday, November 9th.
According to Zacks, analysts expect that Kamada will report full year sales of $24.84 million for the current fiscal year. For the next year, analysts expect that the company will post sales of $126.66 million per share, with estimates ranging from $120.80 million to $132.51 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Kamada.
Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The business had revenue of $32.55 million for the quarter, compared to the consensus estimate of $33.30 million. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The business’s quarterly revenue was up 70.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.04) earnings per share.
KMDA has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of Kamada from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Jefferies Group LLC reissued a “buy” rating and set a $7.00 target price (down previously from $9.00) on shares of Kamada in a research note on Wednesday, August 2nd. TheStreet cut shares of Kamada from a “c-” rating to a “d+” rating in a research note on Tuesday, August 1st. Finally, ValuEngine cut shares of Kamada from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $8.50.
TRADEMARK VIOLATION WARNING: “Kamada Ltd. (KMDA) Expected to Announce Quarterly Sales of $24.84 Million” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/12/kamada-ltd-kmda-expected-to-announce-quarterly-sales-of-24-84-million.html.
A number of institutional investors have recently added to or reduced their stakes in the business. Edmond DE Rothschild Holding S.A. increased its stake in Kamada by 10.5% during the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 4,000 shares during the period. Vanguard Group Inc. increased its stake in Kamada by 6.5% during the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after buying an additional 28,382 shares during the period. Renaissance Technologies LLC increased its stake in Kamada by 16.7% during the 1st quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after buying an additional 37,800 shares during the period. Navellier & Associates Inc acquired a new position in Kamada during the 2nd quarter valued at about $303,000. Finally, Paulson & CO. Inc. increased its stake in Kamada by 8.2% during the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after buying an additional 60,000 shares during the period. 7.29% of the stock is currently owned by hedge funds and other institutional investors.
Kamada (NASDAQ KMDA) opened at 4.85 on Thursday. Kamada has a 12 month low of $3.75 and a 12 month high of $8.61. The firm’s market capitalization is $181.39 million. The stock’s 50 day moving average price is $4.64 and its 200-day moving average price is $5.95.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.